Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06733350 · ClinicalTrials.gov registry record · Phase 4

Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance

A Phase 4 study, sponsored by Roswell Park Cancer Institute.

Recruiting
Registry status
Phase 4
Development phase
600
Enrollment target

NCT06733350 is a Phase 4 study that is actively recruiting participants, run by Roswell Park Cancer Institute. The registered enrollment target is 600 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06733350, a Phase 4 study, is actively recruiting participants, sponsored by Roswell Park Cancer Institute.

RECRUITING
Registry status
Phase 4
Development phase
600 participants
Enrollment target

Study Summary

This phase IV trial studies the effects of testosterone replacement therapy (TRT) on treatment outcomes in hypogonadal men with prostate cancer that has not spread to other parts of the body (localized) and who are on active surveillance (AS). AS in prostate cancer involves closely watching the patient's condition through regular physical exams and blood tests, but not giving treatment unless there are changes in test results. It can be a practical alternative to treatment in localized prostate cancer. Hypogonadal men have low testosterone associated with symptoms such as low libido and erectile problems. TRT can be used to treat hypogonadism by increasing testosterone levels, which may improve associated symptoms. TRT is often not used in men with prostate cancer due to concerns it may lead to the cancer growing or spreading. This may lead hypogonadal men to have a poor quality of life or to discontinue AS. TRT may improve treatment and quality of life outcomes in hypogonadal men with localized prostate cancer on active surveillance.

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Magnetic Resonance Imaging
  • OTHER Questionnaire Administration
  • PROCEDURE Biopsy of Prostate
  • OTHER Patient Observation

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2025-01-15
Est. Completion 2029-01-15
Phase Phase 4

Sponsor

Roswell Park Cancer Institute

365 total trials

What the Registry Record Tells You About NCT06733350

The ClinicalTrials.gov registry entry for NCT06733350 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT06733350 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT06733350 about?

NCT06733350 is a clinical study titled "Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance". This phase IV trial studies the effects of testosterone replacement therapy (TRT) on treatment outcomes in hypogonadal men with prostate cancer that has not spread to other parts of the body (localized) and who are on active surveillance (AS). AS in prostate cancer involves closely watching the pati...

What is the current status of trial NCT06733350?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 600 participants. The study started on 2025-01-15. Estimated completion is 2029-01-15.

What interventions are being tested in trial NCT06733350?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Questionnaire Administration (OTHER), Biopsy of Prostate (PROCEDURE), Patient Observation (OTHER).

Who is sponsoring clinical trial NCT06733350?

This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.